Nasdaq · CIK 0001574094
RNXT RenovoRx, Inc.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $1.28 on Oct 9, 2026, +75% from the 52-week low and -49% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
RNXTOct 9, 2026 · close 1.28
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at RenovoRx, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Ramtin Agah Chief Medical Officer buy | $9,975 10,000 shares | +1% | +36% from low-35% from high | |
| 36Weak | Ramtin Agah Chief Medical Officer buy | $8,424 9,795 shares | +1% | +15% from low-45% from high | |
| 31Weak | Ramtin Agah Chief Medical Officer buy | $169 205 shares | +0% | +19% from low-43% from high | |
| 46Moderate | Shaun Bagai Chief Executive Officer buy | $4,507 5,000 shares | +1% | +23% from low-42% from high | |
| 41Moderate | Shaun Bagai Chief Executive Officer buy | $4,262 5,000 shares | +2% | +19% from low-44% from high | |
| 36Weak | Ramtin Agah Chief Medical Officer buy | $10k 12,000 shares | +2% | +15% from low-45% from high | |
| 36Weak | Ramtin Agah Chief Medical Officer buy | $9,600 10,000 shares | +1% | +28% from low-39% from high | |
| 33Weak | Ramtin Agah Chief Medical Officer buy | $18k 22,000 shares | +3% | +9% from low-48% from high | |
| 33Weak | Shaun Bagai Chief Executive Officer buy | $9,297 10,000 shares | +3% | +22% from low-39% from high | |
| 25Weak | Ramtin Agah Chief Medical Officer buy | $29k 21,000 shares | +3% | - | |
| 43Moderate | Ramtin Agah Chief Medical Officer buy | $14k 15,000 shares | +1% | +17% from low-42% from high | |
| 53Moderate | Shaun Bagai Chief Executive Officer buy | $6,821 7,500 shares | +2% | +17% from low-42% from high | |
| 53Moderate | Ramtin Agah Chief Medical Officer buy | $16k 20,000 shares | +2% | 0% from low-50% from high | |
| 53Moderate | Ramtin Agah Chief Medical Officer buy | $24k 30,000 shares | +3% | +5% from low-46% from high | |
| 63Notable | Shaun Bagai Chief Executive Officer buy | $8,300 10,000 shares | +3% | +5% from low-46% from high | |
| 56Moderate | Ron Kocak VP Controller and PAO buy | $10k 12,595 shares | - | +1% from low-48% from high | |
| 48Moderate | Ramtin Agah Chief Medical Officer buy | $22k 26,000 shares | +3% | +1% from low-48% from high | |
| 54Moderate | Laurence Marton director buy | $10k 12,050 shares | +36% | +1% from low-48% from high | |
| 58Moderate | Shaun Bagai Chief Executive Officer buy | $8,300 10,000 shares | +3% | 0% from low-49% from high |
Transactions
The last 45 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Laurence Marton director | AGrant or award Stock Options (right to buy)derivative | +55,924 | $0.00 | $0 | 55,924 | 10 d ago |
| Oct 1, 2026 | Una S Ryan director | AGrant or award Stock Options (right to buy)derivative | +55,924 | $0.00 | $0 | 55,924 | 10 d ago |
| Oct 1, 2026 | Robert J. Spiegel director | AGrant or award Stock Options (right to buy)derivative | +55,924 | $0.00 | $0 | 55,924 | 10 d ago |
| Oct 1, 2026 | K. Angela Macfarlane director | AGrant or award Stock Options (right to buy)derivative | +55,924 | $0.00 | $0 | 55,924 | 10 d ago |
| Sep 10, 2026 | Mark Voll Chief Financial Officer | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 222,380 | 27 d ago |
| Mar 20, 2026 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stockindirect: The Bagai Family Trust | +24,300 | - | - | 313,357 | Mar 24, 2026 |
| Mar 20, 2026 | Shaun Bagai Chief Executive Officer | POpen-market purchase Warrantsderivativeindirect: The Bagai Family Trust | +12,150 | - | - | 12,150 | Mar 24, 2026 |
| Jan 21, 2026 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +10,000 | $1.00 | $9,975 | 798,460 | Jan 22, 2026 |
| Dec 31, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +9,795 | $0.86 | $8,424 | 788,460 | Jan 5, 2026 |
| Dec 30, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +205 | $0.83 | $169 | 778,665 | Jan 2, 2026 |
| Dec 18, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $0.90 | $4,507 | 340,040 | Dec 22, 2025 |
| Dec 17, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $0.85 | $4,262 | 335,040 | Dec 19, 2025 |
| Dec 16, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +12,000 | $0.85 | $10k | 778,460 | Dec 17, 2025 |
| Dec 5, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +10,000 | $0.96 | $9,600 | 766,460 | Dec 8, 2025 |
| Nov 21, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +10,000 | $0.80 | $8,000 | 744,460 | Nov 24, 2025 |
| Nov 24, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +12,000 | $0.80 | $9,600 | 756,460 | Nov 24, 2025 |
| Oct 1, 2025 | Laurence Marton director | AGrant or award Stock Options (right to buy)derivative | +47,640 | $0.00 | $0 | 47,640 | Oct 3, 2025 |
| Oct 1, 2025 | K. Angela Macfarlane director | AGrant or award Stock Options (right to buy)derivative | +47,640 | $0.00 | $0 | 47,640 | Oct 2, 2025 |
| Oct 1, 2025 | Una S Ryan director | AGrant or award Stock Options (right to buy)derivative | +47,640 | $0.00 | $0 | 47,640 | Oct 2, 2025 |
| Oct 1, 2025 | Robert J. Spiegel director | AGrant or award Stock Options (right to buy)derivative | +47,640 | $0.00 | $0 | 47,640 | Oct 2, 2025 |
| Aug 22, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $0.95 | $4,748 | 325,040 | Aug 26, 2025 |
| Aug 25, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $0.91 | $4,549 | 330,040 | Aug 26, 2025 |
| Jul 1, 2025 | Ramtin Agah Chief Medical Officer | AGrant or award Stock Optionderivative | +63,636 | $0.00 | $0 | 63,636 | Jul 3, 2025 |
| Jul 1, 2025 | Ron Kocak VP, Controller and PAO | AGrant or award Stock Optionderivative | +41,600 | $0.00 | $0 | 41,600 | Jul 3, 2025 |
| Jul 1, 2025 | Shaun Bagai Chief Executive Officer | AGrant or award Stock Optionderivative | +102,498 | $0.00 | $0 | 102,498 | Jul 3, 2025 |
| Jul 1, 2025 | Leesa Gentry Chief Clinical Officer | AGrant or award Stock Optionderivative | +6,619 | $0.00 | $0 | 6,619 | Jul 3, 2025 |
| Jun 5, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +21,000 | $1.40 | $29k | 734,460 | Jun 9, 2025 |
| Apr 22, 2025 | Ramtin Agah Chief Medical Officer | GGift Common Stock | -400,000 | $0.00 | $0 | 713,460 | Jun 6, 2025 |
| May 2, 2025 | Laurence Marton director | MOption exercise Common Stock | +20,480 | $0.15 | $3,072 | 66,164 | May 6, 2025 |
| May 2, 2025 | Laurence Marton director | MOption exercise Stock Option (right to buy)derivative | -20,480 | $0.00 | $0 | 0 | May 6, 2025 |
| Apr 15, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +15,000 | $0.90 | $14k | 1,113,460 | Apr 17, 2025 |
| Apr 14, 2025 | Leesa Gentry Chief Clinical Officer | AGrant or award Stock Optionderivative | +26,477 | $0.00 | $0 | 26,477 | Apr 16, 2025 |
| Apr 14, 2025 | Ron Kocak VP, Controller and PAO | AGrant or award Stock Optionderivative | +166,400 | $0.00 | $0 | 166,400 | Apr 16, 2025 |
| Apr 14, 2025 | Shaun Bagai Chief Executive Officer | AGrant or award Stock Optionderivative | +409,992 | $0.00 | $0 | 409,992 | Apr 16, 2025 |
| Apr 14, 2025 | Ramtin Agah Chief Medical Officer | AGrant or award Stock Optionderivative | +254,542 | $0.00 | $0 | 254,542 | Apr 16, 2025 |
| Apr 15, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +7,500 | $0.91 | $6,821 | 320,040 | Apr 16, 2025 |
| Apr 11, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +20,000 | $0.80 | $16k | 1,098,460 | Apr 14, 2025 |
| Apr 9, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +30,000 | $0.81 | $24k | 1,078,460 | Apr 10, 2025 |
| Apr 9, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $0.83 | $8,300 | 312,540 | Apr 10, 2025 |
| Apr 8, 2025 | Ron Kocak VP Controller and PAO | POpen-market purchase Common Stock | +95 | $0.80 | $76 | 95 | Apr 10, 2025 |
| Apr 9, 2025 | Ron Kocak VP Controller and PAO | POpen-market purchase Common Stock | +6,000 | $0.80 | $4,800 | 6,095 | Apr 10, 2025 |
| Apr 10, 2025 | Ron Kocak VP Controller and PAO | POpen-market purchase Common Stock | +6,500 | $0.79 | $5,135 | 12,595 | Apr 10, 2025 |
| Apr 8, 2025 | Ramtin Agah Chief Medical Officer | POpen-market purchase Common Stock | +26,000 | $0.84 | $22k | 1,048,460 | Apr 9, 2025 |
| Apr 8, 2025 | Laurence Marton director | POpen-market purchase Common Stock | +12,050 | $0.85 | $10k | 45,684 | Apr 9, 2025 |
| Apr 7, 2025 | Shaun Bagai Chief Executive Officer | POpen-market purchase Common Stock | +10,000 | $0.83 | $8,300 | 302,540 | Apr 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Ramtin AgahChief Medical Officer
- Shaun BagaiChief Executive Officer
- Leesa GentryChief Clinical Officer
- Ron KocakVP, Controller and PAO
- K. Angela Macfarlanedirector
- Laurence Martondirector
- Una S Ryandirector
- Robert J. Spiegeldirector
- Mark VollChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.